News: MedPharm Announces Appointment of New U.S. Director of Analytical
March 30, 2023
MedPharm, a global CDMO focused on topical and transdermal development and manufacturing, recently announced the appointment of a new U.S. Director of Analytical, Monica Germann, and the restructuring of its analytical suite in the U.S. This appointment, as well as the restructuring of the department, will create new growth opportunities for the organization, as well as efficiency gains and harmonization of analytical services across all MedPharm sites.
MedPharm currently provides a comprehensive range of analytical and bioanalytical method development and validation services to the pharmaceutical industry. This department restructure, which includes combining MedPharm’s analytical and bioanalytical teams, will allow the CDMO to build on its existing LC-MS/MS, LCUV, UPLC, and qRT-PCR testing services.
Speaking on this announcement, MedPharm CSO Jon Lenn said: “Monica came to MedPharm highly recommended and immediately blew us away with her technical skills and management style. Her background in performance testing and bioanalysis made her the ideal candidate for this position, and we’re excited to see what the future holds for the entire department.”
Prior to joining MedPharm in 2022, Germann worked for multiple life science organizations in the Research Triangle Park area, including Covance and Aerie Pharmaceuticals. In addition to her bioanalytical and mass spectrometry expertise, Germann has more than 20 years of experience working within FDA guidelines and GxP regulations.
When asked about the future of MedPharm’s Analytical department, Germann said: “I’m looking forward to working with this outstanding team to continue supporting drug development here at MedPharm. We will continue working to broaden our analytical activities while providing high-quality data and meeting the challenges of more complex drugs and drug products.”
MedPharm supports clients around the world from early-stage development through to the commercialization of their innovations, with a focus on topical and transdermal products. Find out more about its services here.
MedPharm is the world’s leading contract provider of topical and transdermal formulation development and manufacturing services. Our experts specialize in reducing risk and accelerating development times for generic and proprietary pharmaceutical customers through cost-effective and industry-leading performance testing models. Well-established as the global leader in dermal and transdermal product development, MedPharm also offers innovative solutions for airway, ophthalmic, otic, ungual, and other topical preparations. With locations in both the US and the UK, MedPharm is the CDMO of choice for developers around the globe.